Gilead Sciences Inc. GILD -1.37% will cease contemplating particular person emergency requests for its experimental coronavirus drug, besides in sure circumstances, because it grapples with overwhelming demand, the corporate stated Saturday.
Gilead and different researchers are conducting multiple clinical trials of the drug, remdesivir, in sufferers hospitalized by the virus. Preliminary examine information can be out there within the coming weeks, Gilead Chief Govt Daniel O’Day wrote in an open letter posted on the corporate’s web site.
Not all sufferers can get into the research, both as a result of they don’t meet the medical eligibility standards or aren’t being handled at a hospital collaborating within the trials. For severely ailing sufferers who can’t get right into a examine, medical doctors could make a “compassionate use” request for unapproved medication, which should be evaluated on a case-by-case foundation.
“This works effectively when there’s solely a restricted variety of requests—as is generally the case—however the system can’t help and course of the overwhelming variety of purposes we have now seen with Covid-19,” Mr. O’Day stated within the letter, referring to the illness brought on by the brand new coronavirus.